Multibagger Selection: DeepSeek's picks
DeepSeek picked INOD, ONDS, SVRA, AQST, INBX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 78% | — | — |
| 2 | ONDS | — | 72% | — | — |
| 3 | SVRA | — | 70% | — | — |
| 4 | AQST | — | 65% | — | — |
| 5 | INBX | — | 68% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -3.34% | -4.22% | 1.15x | 0 |
The model's market view
Small and mid-cap equities are in a selective, catalyst-driven environment as of late October 2026. AI infrastructure spending remains the strongest secular growth driver for profitable small caps, while binary biotech catalysts (PDUFA dates) offer asymmetric event-driven setups. Liquidity is adequate for institutional participation, but dilution risk and financing overhangs require careful balance-sheet screening. The most attractive multibagger candidates combine verified revenue acceleration, visible margin expansion and a specific, time-bound catalyst within the next 12 months.
Why each pick
INOD
Innodata is the highest-quality AI infrastructure small cap in this set. Q2 2026 revenue rose 58% year over year to $92.1 million, adjusted gross margin expanded to 49% from 40%, and adjusted EBITDA grew 92%, demonstrating operating leverage. The company reiterated full-year 2026 revenue growth guidance of 40% or more. It trades at roughly 5x sales and about 40x trailing earnings, with real free cash flow and a market capitalization under $2.1 billion. The balance sheet is debt-free with $117.4 million in cash and short-term investments as of 31 March 2026, and no borrowings on its expanded $50 million credit facility. The main risk is customer concentration in large AI programs, and the stock has already had a large run, so multiple compression is possible. The next catalyst is Q3 2026 earnings (expected early November 2026), which will test whether the 40%+ growth trajectory is intact.
ONDS
Ondas Holdings has transformed from a speculative small cap into a high-growth defense and industrial drone platform. Q2 2026 revenue reached $83.8 million, up 13x year over year and 67% sequentially, with pro forma backlog of $757 million and adjusted gross margin around 50%. The company raised its 2026 revenue target to at least $390 million after a record quarter, and it ended Q1 2026 with $1.48 billion in cash equivalents and virtually no debt, removing near-term financing risk. The revenue trajectory is extraordinary, but the stock is not cheap at roughly 9x annualized sales, and the company has a history of acquisitions that could complicate organic growth comparisons. The catalyst is Q3 2026 earnings in November 2026, where management is expected to update on the $390 million revenue target and backlog conversion.
SVRA
Savara is a binary biotech catalyst play with a PDUFA date of 22 November 2026 for MOLBREEVI (inhaled GM-CSF) in autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with a $500 million-plus market opportunity. The company has approximately $203 million in cash and short-term investments as of 31 March 2026, with debt of about $30 million, funding operations into the second half of 2027. The stock is a pure regulatory catalyst: approval would transform the revenue base from essentially zero to a commercial launch, while a complete response letter would be devastating. The valuation at roughly $1 billion market cap already prices in a high probability of approval, so the upside on approval may be more modest than a typical binary event. The key catalyst is the 22 November 2026 PDUFA date.
AQST
Aquestive Therapeutics is a smaller, earlier-stage binary catalyst than Savara. The FDA accepted the Anaphylm NDA resubmission with a PDUFA date of 16 March 2027. Anaphylm is an oral epinephrine film for severe allergic reactions, and if approved, it would be the first non-injectable epinephrine product, targeting a large market currently dominated by auto-injectors. The company had $98.5 million in cash as of 30 June 2026, plus a $150 million Oaktree debt facility and $75 million in launch funding from RTW upon approval, which covers commercialization costs. Revenue from existing products was $13.8 million in Q2 2026, up 38% year over year. The stock trades at roughly $4, well below the sell-side average target, suggesting skepticism about approval. The catalyst is the March 2027 PDUFA, and approval would be transformative.
INBX
Inhibrx Biosciences is a clinical-stage oncology company with a PDUFA date of 14 April 2027 for ozekibart in conventional chondrosarcoma, a rare bone cancer with limited treatment options. The BLA was accepted without filing review issues, and the company has over $200 million in cash, providing runway through the PDUFA. The stock trades around $98 per share, and the market cap of roughly $1.45 billion reflects a meaningful probability of approval. Ozekibart has shown strong progression-free survival and disease-control data, but the chondrosarcoma market is small, so peak sales may be limited unless the label expands. The catalyst is the April 2027 PDUFA, and approval would validate the platform and provide a commercial launch.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | URGN, AXTI, ETON, INOD, BKSY |
| Gemini 3 Pro | BHVN, SG, SMR, JOBY, RDW |
| Grok 4.5 | NRIX, INOD, LQDA, CELC, APLD |
| Muse Spark 1.1 | KOD, CAPR, IVA, RCUS, TPC |
| GPT-6 | AMPX, BKSY, RCAT, ENVX, OUST |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.